Updated on 4 May 2012
Giving his view on China's focus on developing international standard vaccines and the potential of country's human capital to lead the task, Dr Wu Ke opines, "China has the biggest biotech-related talent pool in the world having about 1.7 million natural sciences graduates annually and among them, about a hundred thousand graduates are from different fields of life sciences. These well-educated talents can evolve to form the main force for the development of the vaccine industry in China. Meanwhile, the IP environment has improved dramatically in the past few years. China is now the second largest country in patent application as well as scientific paper publications, and will surpass the US before 2020 or even earlier."
"The central and local governments give strong support to hi-tech development, and vaccine has been included in the national development strategy. Capital from governments along with private funds are now active in seeking any opportunity in this area. Last year, the Chinese vaccine regulatory system passed the assessment from WHO. Made-in-China vaccines will be accepted by more countries soon and will be beneficial to more population worldwide," says Dr Wu Ke. He is hopeful that BravoBio will be able to position itself in the international market very soon.
BravoBio will be fully engaged in the integration of various resources by being a bridge between investors and industries, a bond between academies and industries, a mediator between domestic and international partners. Quality and efficiency will be the two core competences of BravoBio, believes Dr Wu Ke.